AstraZeneca PLC header image

AstraZeneca PLC

AZN

Equity

ISIN GB0009895292 / Valor 982352

LSE London Stock Exchange, SETS (2026-02-25)

GBP 152.18-0.70%

AstraZeneca PLC
UMushroom community rating:

4.04 20 votes No rating yet

NegativeNeutralPositive

About company

AstraZeneca PLC is a global pharmaceutical company with a focus on the discovery, development, and commercialization of prescription medicines across various therapy areas. The company is science-led and patient-focused, aiming to address unmet medical needs by bringing innovative medicines to market. AstraZeneca operates in key therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with a growing pipeline in rare diseases. Its business strategy emphasizes growth through innovation, leveraging advanced therapeutic modalities and engaging in strategic partnerships to enhance healthcare outcomes. AstraZeneca's commitment to healthcare extends to improving access to its medicines globally, ensuring it plays a significant role in transforming the future of healthcare.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

27.5%1Y

37.1%3Y

116%5Y

Performance

26.4%1Y

23.7%3Y

23.6%5Y

Volatility

319416 M

Market cap (USD)

813,819

Daily traded volume (Shares)

104.82 / 103.6

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.04

20 votes

Performance:

3.67

Innovation:

4.28

Society:

3.78

Nature:

3.46

Aran Grant

United Kingdom, 09 Nov 2025

Health stocks nice and stable

Deny Purwanto

United Kingdom, 09 Nov 2025

.

Korbinian Kramer

United Kingdom, 08 Nov 2025

Strong growth due to the comapnies strength in innovation and high drug demand

EQUITIES OF THE SAME SECTOR

bioMerieux SA

bioMerieux SA Valor: 38147803

Annual Return

-50%0%+50%

Risk level

110

0.78%EUR 96.40

Siemens Healthineers AG

Siemens Healthineers AG Valor: 40652181

Annual Return

-50%0%+50%

Risk level

110

1.56%EUR 42.39

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA Valor: 332902

Annual Return

-50%0%+50%

Risk level

110

0.43%EUR 51.32

Fresenius Medical Care AG

Fresenius Medical Care AG Valor: 520878

Annual Return

-50%0%+50%

Risk level

110

2.56%EUR 39.22

Evolent Health Inc

Evolent Health Inc Valor: 28153126

Annual Return

-50%0%+50%

Risk level

110

22.66%USD 3.14

Vita 34 AG

Vita 34 AG Valor: 2333201

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 5.20

Maternus-Kliniken AG

Maternus-Kliniken AG Valor: 335800

Annual Return

-50%0%+50%

Risk level

110

1.06%EUR 0.95

QuidelOrtho Corporation

QuidelOrtho Corporation Valor: 119356965

Annual Return

-50%0%+50%

Risk level

110

6.38%USD 23.33

iRhythm Technologies Inc

iRhythm Technologies Inc Valor: 34117792

Annual Return

-50%0%+50%

Risk level

110

-0.88%USD 135.90

Novartis Inc

Novartis Inc Valor: 1200526

Annual Return

-50%0%+50%

Risk level

110

-1.31%CHF 128.10

SIX

FactSet

Clearbit

Logos provided by Clearbit